This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

SUNIL ABHYANKAR, MD; SREEDHAR P. RAO, MD; LAUREEN POLLIO, RN; SCOTT T. MILLER, MD
Department of Pediatrics Division of Hematology/Oncology State University of New York–Health Science Center at Brooklyn Brooklyn, NY 11203

Am J Dis Child. 1988;142(9):918.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—Dacarbazine, an imidazole carboxamide, has been used mainly in the treatment of malignant melanoma, sarcomas, and Hodgkin's disease.1,2 It has not been used as widely in the treatment of pediatric malignancies; however, the drug has been shown to be effective in the treatment of neuroblastoma.³ Adverse effects of this drug include anorexia, nausea, vomiting, bone marrow suppression, hepatotoxicity, an influenzalike syndrome, facial flushing and parasthesia, photosensitivity reactions, and veno-occlusive disease.^4,5 To our knowledge, hypersensitivity reactions have not been reported. We describe a child in whom anaphylactic shock developed while receiving dacarbazine infusion.

Patient Report.—The patient, a 3-year-old girl with widespread neuroblastoma, was hospitalized to receive chemotherapy consisting of cyclophosphamide (750 mg/m² intravenously [IV] once on day 1), vincristine (1.5 mg/m² IV on day 5), and dacarbazine (25 mg/m² one-hour IV infusion on days 1 through 5). She had no known allergies. The . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?